Drug Trial Radar · NCT03407482
An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Dec 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
160
Actual
Start
Jan 9, 2018
Primary completion
Nov 20, 2019
Study completion Nov 20, 2019
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jan 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 76 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase II, multicenter, open-label extension (OLE) study will evaluate the long-term safety and efficacy of GDC-0853 in participants with systemic lupus erythematosus (SLE) who have completed Study GA30044 (NCT02908100) up to 48 weeks.
Conditions
- Lupus Erythematosus, Systemic
Interventions
GDC-0853Drug
Participants received GDC-0853 at a dose of 200mg, as per the dosing schedule described above.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Adverse Events (AEs)Time frame: Baseline up until 8 weeks after the last dose of study drug (up to 56 weeks)
Locations
53 sites in 11 countries. Site status is shown where the registry gives one.
Valerius Medical Group
Los Alamitos, California
RASF-Clinical Research Center
Boca Raton, Florida
Bay Area Arthritis and Osteoporosis
Brandon, Florida
Clinical Research of West Florida
Clearwater, Florida
Institute of Arthritis Research
Idaho Falls, Idaho
Ochsner Clinic Foundation
Baton Rouge, Louisiana
Shanahan Rheumatology & Immunology, PLLC
Raleigh, North Carolina
Tekton Research Inc
Austin, Texas
Accurate Clinical Research
Houston, Texas
Accurate Clinical Research
Houston, Texas
Arthritis Clinic Of Central Texas
San Marcos, Texas
APRILLUS
Buenos Aires, Argentina
Hospital Italiano de La Plata
La Plata, Argentina
CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica
San Juan, Argentina
Centro Médico Privado de Reumatología
San Miguel de Tucumán, Argentina
CIP - Centro Internacional de Pesquisa
Goiânia, Goiás, Brazil
Centro Mineiro de Pesquisa - CMIP
Juiz de Fora, Minas Gerais, Brazil
Edumed - Educação e Saúde SA
Curitiba, Paraná, Brazil
Centro de Pesquisas em Diabetes - CPD
Porto Alegre, Rio Grande do Sul, Brazil
Clinica de Neoplasias Litoral
Itajaí, Santa Catarina, Brazil
Faculdade de Medicina do ABC - FMABC
Santo André, São Paulo, Brazil
Centro Multidisciplinar de Estudos Clínicos - CEMEC*X*
Santo André, São Paulo, Brazil
Centro de Pesquisas Clinicas; CPCLIN
São Paulo, São Paulo, Brazil
Hospital Abreu Sodré - AACD
São Paulo, São Paulo, Brazil
MHAT Plovdiv
Plovdiv, Bulgaria
Medical Center "Teodora", EOOD
Rousse, Bulgaria
Medical Center Excelsior OOD
Sofia, Bulgaria
UMHAT "Sv. Ivan Rilski", EAD
Sofia, Bulgaria
MC "Synexus - Sofia", EOOD
Sofia, Bulgaria
Medical Center "Nov Rehabilitatsionen Tsentar", EOOD
Stara Zagora, Bulgaria
CTR Estudios SPA
Providencia, Chile
Dermacross
Santiago, Chile
Centro de Estudios Reumatologi
Santiago, Chile
Biomedica
Santiago, Chile
Centro Integral de Reumatologia del Caribe SAS CIRCARIBE SAS
Barranquilla, Colombia
Centro de Investigacion Medico Asistencial S.A.S
Barranquilla, Colombia
Medicity S.A.S.
Bucaramanga, Colombia
Servimed S.A.S.
Bucaramanga, Colombia
Hospital Pablo Tobon Uribe
Medellín, Colombia
Hospital Angeles Lindavista
México, Mexico
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.